HeyJaredNnenna Ohaka
- Indexed articles, last 90 days
- 53
- Latest publication
- Oct 1, 2026
- Outlet visibility, for SCM
- Top 10M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Sanofi and Regeneron deepen immunology alliance (opens the original)
Read excerpt
Sanofi and Regeneron have built on their two-decade antibody partnership, adding four long-acting immunology candidates in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront from Sanofi, with an additional $7 billion available through development, regulatory, and commercial milestones. The companies will share development and commercialisation costs equally and split any future profits 50:50 globally. Regeneron will lead research and development, while Sanofi will lead glob
Europe's biotech funding gap threatens growth (opens the original)
Read excerpt
Despite world class science, experts discussed why Europe's biotech sector struggles with regulatory fragmentation and insufficient private capital. Europe is largely considered to be a powerful player in global life sciences, with the Nordics standing out for their ability to innovate. One of Europe’s advantages is its talent pool. Last year, the European Union announced its €500 million ($568 million) pledge to support the “best and the brightest researchers and scientists from Europe and arou
How AI-native biotechs are building investor confidence (opens the original)
Read excerpt
Why unique data, clinical focus, and energy costs now define which AI drug developers get funded. The pitch for AI-enabled biotech has never been more compelling, and investors have heard most of it before. A panel discussion at LSX Congress USA in Boston, Massachusetts, delved into what distinguishes AI that is investable from what merely sounds like it. “Speed only becomes an advantage when it is backed by evidence,” Michelle Chen, president and CEO of Form Bio, told the audience. Chen traced
The M&A paradox: Why signing the deal is just the beginning (opens the original)
Read excerpt
Panelists at LSX USA Congress unpacked what separates a successful acquisition from an expensive mistake. “Signing an M&A deal doesn't create value. It sets the stage for value that has to be created later,” Scott DeWire, global head of business development and licensing at Boehringer Ingelheim, told the audience at LSX USA Congress in Boston, Massachusetts. "Structuring each deal requires balancing the money you've got, the control desired, and the risk that you're willing to take," Rachel Stri
Kasvu raises $34m for non-hallucinogenic drug (opens the original)
Read excerpt
Kasvu Therapeutics has closed a €30 million ($34 million) Series A funding round to advance non-hallucinogenic depression treatment into the clinic. The proceeds will fund investigational new drug (IND)-enabling work on Kasvu's lead program, KTX-0141, ahead of Phase I/Ib trials targeting major depressive disorder (MDD). “There is high unmet need in neuropsychiatry, including depression. 970 million people around the world live with a neuropsychiatric/mental health disorder. Depression itself is
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 10M sites
For SCM, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.